Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Moderna, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CAMBRIDGE, MA / ACCESS NEWSWIRE / MAY 12, 2026 / MODERNA, INC. (NASDAQ:MRNA) TODAY ANNOUNCED IT WAS RANKED NO. 1 ON TIME'S 2026 LIST OF THE WORLD'S MOST IMPACTFUL COMPANIES.

MODERNA RECOGNIZED BY TIME AS ONE OF THE WORLD'S MOST IMPACTFUL COMPANIES

REPORTS FIRST QUARTER REVENUE OF $0.4 BILLION, WITH APPROXIMATELY 80% OF REVENUE FROM INTERNATIONAL MARKETS REPORTS FIRST QUARTER GAAP NET LOSS OF $(1.3) BILLION AND GAAP EPS OF $(3.40), INCLUDING $0.9 BILLION NON-RECURRING LITIGATION SETTLEMENT CHARGE REITERATES PLAN TO DELIVER UP TO 10% REVENUE GROWTH AND GAAP OPERATING EXPENSE REDUCTIONS IN 2026, EXCLUDING THE NON-RECURRING LITIGATION SETTLEMENT CHARGE ADVANCED INFECTIOUS DISEASE PORTFOLIO WITH KEY REGULATORY MILESTONES IN THE EU, INCLUDING APPROVAL OF MNEXSPIKE AND MCOMBRIAX, MODERNA'S FLU PLUS COVID COMBINATION VACCINE INITIATED PHASE 3 CLINICAL STUDY EVALUATING INTISMERAN AUTOGENE AS MONOTHERAPY AND IN COMBINATION WITH KEYTRUDA QLEX FOR TREATMENT OF HIGH-RISK STAGE 1 NON-SMALL CELL LUNG CANCER CAMBRIDGE, MA / ACCESS NEWSWIRE / MAY 1, 2026 / MODERNA, INC. (NASDAQ:MRNA) TODAY REPORTED FINANCIAL RESULTS AND PROVIDED BUSINESS UPDATES FOR THE FIRST QUARTER OF 2026. "THE MODERNA TEAM DELIVERED A GREAT START TO THE YEAR, DRIVING SIGNIFICANT REVENUE GROWTH AND SUBSTANTIAL COST REDUCTIONS BUILDING ON ACTIONS TAKEN IN 2025.

MODERNA REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

MODERNA TO HOST AN INVESTOR EVENT VIA WEBCAST ON MONDAY, JUNE 1 AT 6:15 PM CDT CAMBRIDGE, MA / ACCESS NEWSWIRE / APRIL 21, 2026 / MODERNA, INC. (NASDAQ:MRNA) TODAY ANNOUNCED THAT THREE ABSTRACTS ON ITS INVESTIGATIONAL MRNA THERAPEUTICS HAVE BEEN ACCEPTED FOR PRESENTATION AT THE 2026 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING, WHICH WILL BE HELD MAY 29 - JUNE 2 IN CHICAGO, IL. THE PRESENTATION DETAILS ARE AS FOLLOWS: ORAL PRESENTATION: ABSTRACT #9500: INDIVIDUALIZED NEOANTIGEN THERAPY INTISMERAN AUTOGENE (INTISMERAN) PLUS PEMBROLIZUMAB (PEMBRO) IN RESECTED MELANOMA: 5-YEAR UPDATE OF THE KEYNOTE-942 STUDYSESSION TYPE/TITLE: ORAL ABSTRACT SESSION - MELANOMA/SKIN CANCERSDATA & TIME: JUNE 1, 8:00 AM - 11:00 AM CTPRESENTER: MATTEO S.

MODERNA ANNOUNCES DATA TO BE PRESENTED AT 2026 ASCO ANNUAL MEETING

MCOMBRIAX IS THE WORLD'S FIRST FLU PLUS COVID COMBINATION VACCINE TO RECEIVE MARKETING AUTHORIZATION AND MODERNA'S FOURTH AUTHORIZED PRODUCT MCOMBRIAX WILL BE MADE AVAILABLE IN THE EUROPEAN UNION, SUBJECT TO NATIONAL REGULATORY AND ACCESS PROCEDURES CAMBRIDGE, MA / ACCESS NEWSWIRE / APRIL 21, 2026 / MODERNA, INC. (NASDAQ:MRNA) TODAY ANNOUNCED THAT THE EUROPEAN COMMISSION (EC) HAS GRANTED MARKETING AUTHORIZATION FOR MCOMBRIAX (MRNA-1083), THE COMPANY'S MRNA COMBINATION VACCINE FOR ACTIVE IMMUNIZATION FOR THE PREVENTION OF INFLUENZA DISEASE AND COVID-19 CAUSED BY SARS-COV-2 IN INDIVIDUALS 50 YEARS OF AGE AND OLDER. THIS MARKETING AUTHORIZATION FOLLOWS THE POSITIVE OPINION FROM THE EUROPEAN MEDICINES AGENCY'S (EMA) COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) AND IS VALID IN ALL 27 EUROPEAN UNION MEMBER STATES, AS WELL AS ICELAND, LIECHTENSTEIN AND NORWAY.

MODERNA RECEIVES EUROPEAN COMMISSION MARKETING AUTHORIZATION FOR MCOMBRIAX, MODERNA'S MRNA COMBINATION VACCINE AGAINST INFLUENZA AND COVID-19

CAMBRIDGE, MA / ACCESS NEWSWIRE / APRIL 21, 2026 / MODERNA, INC. (NASDAQ:MRNA), TODAY ANNOUNCED ITS PARTICIPATION IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES: BOFA SECURITIES 2026 HEALTHCARE CONFERENCE, ON TUESDAY, MAY 12TH AT 11:20AM PT RBC 2026 GLOBAL HEALTHCARE CONFERENCE, ON TUESDAY, MAY 19TH AT 10:00 AM ET BERNSTEIN'S 42ND ANNUAL STRATEGIC DECISIONS CONFERENCE, THURSDAY, MAY 28TH AT 10:00AM ET A LIVE WEBCAST OF EACH OF THESE PRESENTATIONS WILL BE AVAILABLE UNDER "EVENTS AND PRESENTATIONS" IN THE INVESTORS SECTION OF THE MODERNA WEBSITE AT INVESTORS.MODERNATX.COM. A REPLAY OF EACH WEBCAST WILL BE ARCHIVED ON MODERNA'S WEBSITE FOR AT LEAST 30 DAYS FOLLOWING THE PRESENTATION.

MODERNA TO PRESENT AT UPCOMING CONFERENCES IN MAY 2026

CAMBRIDGE, MA / ACCESS NEWSWIRE / APRIL 15, 2026 / MODERNA, INC. (NASDAQ:MRNA) TODAY ANNOUNCED THAT IT WILL HOST A LIVE CONFERENCE CALL AND WEBCAST AT 8:00 A.M. ET ON FRIDAY, MAY 1,2026 TO REPORT ITS FIRST QUARTER 2026 FINANCIAL RESULTS, AND PROVIDE A CORPORATE UPDATE.

MODERNA TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS ON FRIDAY, MAY 1, 2026

MODERNA TO PAY $950 MILLION WITH NO FUTURE ROYALTIES TO RESOLVE ALL GLOBAL LITIGATION; CORRESPONDING CHARGE EXPECTED IN Q1 2026 DISTRICT COURT'S SECTION 1498 DECISION TO BE APPEALED TO THE FEDERAL CIRCUIT COURT OF APPEALS WITH POTENTIAL ADDITIONAL PAYMENT CONTINGENT ON THE OUTCOME; NO ACCRUAL RECORDED FOR POTENTIAL ADDITIONAL PAYMENT AS LOSS IS NOT CONSIDERED PROBABLE 2026 YEAR-END CASH AND CASH EQUIVALENTS NOW EXPECTED TO BE IN THE RANGE OF $4.5 - $5.0 BILLION CAMBRIDGE, MA / ACCESS NEWSWIRE / MARCH 3, 2026 / MODERNA, INC. (NASDAQ:MRNA) TODAY ANNOUNCED THAT IT HAS ENTERED INTO A SETTLEMENT AGREEMENT WITH ARBUTUS BIOPHARMA CORPORATION AND GENEVANT SCIENCES GMBH RESOLVING ALL LITIGATION WORLDWIDE, INCLUDING BETWEEN THE PARTIES IN THE U.S. DISTRICT COURT FOR THE DISTRICT OF DELAWARE. THE SETTLEMENT RESOLVES ALL WORLDWIDE ARBUTUS/GENEVANT LITIGATION RELATED TO SPIKEVAX AND MRESVIA AND PROVIDES CERTAINTY GOING FORWARD FOR MODERNA'S FULL INFECTIOUS DISEASE PORTFOLIO, INCLUDING MNEXSPIKE, MCOMBRIAX AND ITS FUTURE VACCINE PIPELINE, WITH NO FUTURE ROYALTIES OWED.

MODERNA RESOLVES GLOBAL PATENT LITIGATION WITH ARBUTUS/GENEVANT

MODERNA TO PAY GENEVANT AND ARBUTUS $950 MILLION UPFRONT AND AN ADDITIONAL $1.3 BILLION CONTINGENT UPON A FAVORABLE RESOLUTION OF MODERNA'S SECTION 1498 APPEAL IF THE $1.3 BILLION PAYMENT IS REALIZED, THIS SETTLEMENT WILL BE THE LARGEST DISCLOSED PATENT SETTLEMENT PAID IN THE PHARMACEUTICAL INDUSTRY AND THE SECOND LARGEST IN ANY INDUSTRY SETTLEMENT HOLDS MODERNA ACCOUNTABLE FOR INFRINGEMENT AND PROVIDES FOR THE COURT TO ENTER JUDGMENT OF NO INVALIDITY ON THE FOUR GENEVANT/ARBUTUS PATENTS ASSERTED IN THE CASE GENEVANT GRANTS MODERNA A GLOBAL NON-EXCLUSIVE LICENSE TO ITS LNP DELIVERY TECHNOLOGY FOR SM-102-CONTAINING MRNA VACCINES FOR INFECTIOUS DISEASE AND A COVENANT NOT TO SUE FOR CERTAIN GENEVANT/ARBUTUS PATENTS AND MODERNA PRODUCTS, ENDING ALL PATENT-INFRINGEMENT LITIGATION AGAINST MODERNA ARISING FROM ITS UNAUTHORIZED USE OF THE TECHNOLOGY IN ITS COVID-19 VACCINES PFIZER/BIONTECH LITIGATION IS ONGOING IN THE UNITED STATES FOLLOWING A FAVORABLE MARKMAN RULING ISSUED IN SEPTEMBER 2025; COMIRNATY SALES REPRESENT ~2/3 OF GLOBAL COVID-MRNA VACCINE SALES TO DATE ARBUTUS ANNOUNCES THAT IT IS CURRENTLY EVALUATING A RETURN OF CAPITAL TO SHAREHOLDERS FOR THE THIRD QUARTER OF CALENDAR YEAR 2026, IN CONJUNCTION WITH THE UPFRONT PAYMENT ROIVANT WILL HOST AN INVESTOR CALL TO DISCUSS THESE UPDATES TODAY, MARCH 3, 2026, AT 4:45 P.M. ET BASEL, SWITZERLAND AND VANCOUVER, BRITISH COLUMBIA, MARCH 03, 2026 (GLOBE NEWSWIRE) -- GENEVANT SCIENCES, A LEADING NUCLEIC ACID DELIVERY COMPANY WITH WORLD-CLASS PLATFORMS AND A ROBUST LIPID NANOPARTICLE (LNP) PATENT PORTFOLIO AND A SUBSIDIARY OF ROIVANT SCIENCES LTD.

GENEVANT SCIENCES AND ARBUTUS BIOPHARMA ANNOUNCE $2.25 BILLION GLOBAL SETTLEMENT WITH MODERNA

MODERNA TO PAY GENEVANT AND ARBUTUS $950 MILLION UPFRONT AND AN ADDITIONAL $1.3 BILLION CONTINGENT UPON A FAVORABLE RESOLUTION OF MODERNA'S SECTION 1498 APPEAL IF THE $1.3 BILLION PAYMENT IS REALIZED, THIS SETTLEMENT WILL BE THE LARGEST DISCLOSED PATENT SETTLEMENT PAID IN THE PHARMACEUTICAL INDUSTRY AND THE SECOND LARGEST IN ANY INDUSTRY SETTLEMENT HOLDS MODERNA ACCOUNTABLE FOR INFRINGEMENT AND PROVIDES FOR THE COURT TO ENTER JUDGMENT OF NO INVALIDITY ON THE FOUR GENEVANT/ARBUTUS PATENTS ASSERTED IN THE CASE GENEVANT GRANTS MODERNA A GLOBAL NON-EXCLUSIVE LICENSE TO ITS LNP DELIVERY TECHNOLOGY FOR SM-102-CONTAINING MRNA VACCINES FOR INFECTIOUS DISEASE AND A COVENANT NOT TO SUE FOR CERTAIN GENEVANT/ARBUTUS PATENTS AND MODERNA PRODUCTS, ENDING ALL PATENT-INFRINGEMENT LITIGATION AGAINST MODERNA ARISING FROM ITS UNAUTHORIZED USE OF THE TECHNOLOGY IN ITS COVID-19 VACCINES PFIZER/BIONTECH LITIGATION IS ONGOING IN THE UNITED STATES FOLLOWING A FAVORABLE MARKMAN RULING ISSUED IN SEPTEMBER 2025; COMIRNATY SALES REPRESENT ~2/3 OF GLOBAL COVID-MRNA VACCINE SALES TO DATE ROIVANT'S BOARD OF DIRECTORS HAS APPROVED A $1 BILLION SHARE REPURCHASE PROGRAM, INCLUSIVE OF THE $500 MILLION AUTHORIZATION THAT WAS APPROVED IN JUNE 2025 ROIVANT WILL HOST AN INVESTOR CALL TO DISCUSS THESE UPDATES TODAY, MARCH 3, 2026, AT 4:45 P.M. ET BASEL, SWITZERLAND AND LONDON AND NEW YORK, MARCH 03, 2026 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) TODAY ANNOUNCED THAT GENEVANT SCIENCES, A LEADING NUCLEIC ACID DELIVERY COMPANY WITH WORLD-CLASS PLATFORMS AND A ROBUST LIPID NANOPARTICLE (LNP) PATENT PORTFOLIO AND A SUBSIDIARY OF ROIVANT, AND ARBUTUS BIOPHARMA CORPORATION (NASDAQ: ABUS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON INFECTIOUS DISEASE, HAVE ENTERED INTO A $2.25 BILLION GLOBAL SETTLEMENT WITH MODERNA, INC. TO RESOLVE ALL U.S. AND INTERNATIONAL ENFORCEMENT ACTIONS INVOLVING MODERNA'S UNAUTHORIZED USE OF GENEVANT'S AND ARBUTUS' LNP DELIVERY TECHNOLOGY IN ITS COVID-19 VACCINES, INCLUDING S

ROIVANT ANNOUNCES GENEVANT SCIENCES' AND ARBUTUS BIOPHARMA'S $2.25 BILLION GLOBAL SETTLEMENT WITH MODERNA

MCOMBRIAX IS THE WORLD'S FIRST FLU PLUS COVID COMBINATION VACCINE TO RECEIVE A POSITIVE CHMP OPINION RECOMMENDING MARKETING AUTHORIZATION AND REPRESENTS MODERNA'S FOURTH VACCINE TO RECEIVE A POSITIVE CHMP OPINION MCOMBRIAX WILL BE MADE AVAILABLE IN THE EUROPEAN UNION, SUBJECT TO FINAL EUROPEAN COMMISSION AUTHORIZATION AND NATIONAL REGULATORY AND ACCESS PROCEDURES CAMBRIDGE, MASSACHUSETTS / ACCESS NEWSWIRE / FEBRUARY 27, 2026 / MODERNA, INC. (NASDAQ:MRNA) TODAY ANNOUNCED THAT THE EUROPEAN MEDICINES AGENCY'S (EMA) COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) HAS ADOPTED A POSITIVE OPINION RECOMMENDING MARKETING AUTHORIZATION IN THE EUROPEAN UNION FOR MCOMBRIAX (MRNA-1083), MODERNA'S COMBINATION VACCINE INDICATED FOR ACTIVE IMMUNIZATION FOR THE PREVENTION OF INFLUENZA AND COVID-19 CAUSED BY SARS-COV-2 IN INDIVIDUALS 50 YEARS OF AGE AND OLDER. "THE CHMP'S POSITIVE OPINION REPRESENTS AN IMPORTANT MILESTONE FOR RESPIRATORY VIRUS VACCINATION AND FOR MODERNA, WITH THE INTRODUCTION OF THE WORLD'S FIRST FLU PLUS COVID COMBINATION VACCINE.

EUROPEAN MEDICINES AGENCY'S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ADOPTS POSITIVE OPINION RECOMMENDING MARKETING AUTHORIZATION OF MCOMBRIAX, MODERNA'S MRNA COMBINATION VACCINE AGAINST INFLUENZA AND COVID-19

CAMBRIDGE, MASSACHUSETTS / ACCESS NEWSWIRE / FEBRUARY 19, 2026 / MODERNA, INC. (NASDAQ:MRNA), TODAY ANNOUNCED ITS PARTICIPATION IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES: TD COWEN 46TH ANNUAL HEALTHCARE CONFERENCE, ON TUESDAY, MARCH 3RD AT 1:50PM ET BARCLAYS 28TH ANNUAL GLOBAL HEALTHCARE CONFERENCE, ON TUESDAY, MARCH 10TH AT 9:30AM ET A LIVE WEBCAST OF EACH OF THESE PRESENTATIONS WILL BE AVAILABLE UNDER "EVENTS AND PRESENTATIONS" IN THE INVESTORS SECTION OF THE MODERNA WEBSITE AT INVESTORS.MODERNATX.COM. A REPLAY OF EACH WEBCAST WILL BE ARCHIVED ON MODERNA'S WEBSITE FOR AT LEAST 30 DAYS FOLLOWING THE PRESENTATION.

Moderna, Inc.

MRNA

Price

Financial Reports

No items found.

Press Releases

Moderna, Inc.

MRNA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

MRNA